The application is directed to haloalkyl-substituted compounds of Formula (I), wherein R1, R1a, R2, R3, R4’ and E are as defined in the claims. The compounds are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. Pharmaceutical compositions comprising these compounds and their use are also disclosed.
该应用程序针对式(I)的卤代烷基取代化合物,其中R1、R1a、R2、R3、R4'和E如索权中所定义。这些化合物是半胱
氨酸
蛋白酶的
抑制剂,特别是卡托普斯
蛋白酶B、K、L、F和S,因此可用于治疗由这些
蛋白酶介导的疾病。还公开了包含这些化合物的药物组合物及其用途。